Albert Collignon

Université de Caen Basse-Normandie, Caen, Lower Normandy, France

Are you Albert Collignon?

Claim your profile

Publications (8)2.74 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is the third most common haematologic malignancy in European countries, and is usually preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS). Therefore epidemiologic studies of MGUS are very limited in a population-based status. Here we report all new cases of MGUS exhaustively recorded by the Basse-Normandie Regional Registry for Hematologic Malignancies (a French region registry) between January 1997 and December 2005, and analyze outcome of patients until 2009 in term of evolution in MM or death. All cases were analyzed by an expert file review, and MGUS diagnosis was retained for: evidence of a monoclonal component <30g/l and no CRAB criteria (hyperCalcemia, renal insufficiency, anemia, bone lesions). We showed that the world standardized incidence rate (WSR) for MGUS was 3.76±0.26 per 100,000 inhabitants, increasing regularly with age, and that the median overall survival (OS) was 115.9 months (CI 95%: 10.5-130.2 months) with 78.3% patients alive at 5 years (CI 95%: 74.1-81.9%). We also observed a rate of progression to multiple myeloma of 1.41% per year, concordant with previous reports in a reallife exhaustive registry.
    Cancer epidemiology. 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study was designed to present the incidence of all the haematological malignancies (HM) in Basse-Normandie (BN) over the period 1997 to 2005 in patients less than 25years old. BN is an administrative region in the North-West of France, composed of three departments: Calvados, Manche and Orne. We extracted data from the Registre régional des hémopathies malignes de Basse-Normandie, a French registry which belongs to the Association of the French Cancer Registries (Francim). All the HM were coded using the third edition of the International classification for oncologic diseases (ICD-O-3). We compared the clinical and biological descriptive data in patients less than 15years old to those of young adults (15-24years old). A total of 305 new cases of HM were recorded over the period 1997 to 2005. HM were more frequent in men (168 cases) than in women (137 cases). Patients less than 25years old accounted for 4.1% of all HM cases, whereas patients less than 15years old and young adults (15-24years old) represented 2.2% and 1.9% of all cases, respectively. In patients less than 25years old, the overall world-standardized incidence rates (WSR) were 7.67/100,000 (95% CI: 6.31-9.04) in BN (8.08 [6.15-10.02] for men and 7.24 [5.31-9.17] for women). In patients less than 15years, the overall WSR was 7.38/100,000 (6.23-8.52), with no difference between boys (7.57) and girls (7.17). Acute lymphoblastic leukaemia (ALL) was the most frequent HM, WSR=4.02/100,000 (3.16-4.88) (4.30 [3.08-5.53] in men, 3.73 [2.52-4.93] in women), with similar clinical and biological criteria between patients less than 15 years and young adults. In young adults, the overall WSR was 8.21/100,000 (7.47-8.96), similar between men and women (9.02 [7.93-10.12] and 7.37 [6.35-8.38], respectively). Their highest WSR was obtained for Hodgkin lymphomas (HL): 3.37/100,000 (2.89-3.85), similar between men (3.49 [2.8-4.17]) and women (3.25 [2.58-3.93]). The study did not show any significant difference between the Calvados, Manche and Orne departments (except for HL, which seems more frequent in Manche department for 15-24years old cases). There was no evidence of an increased risk for ALL in the subdistricts Beaumont-Hague and Les Pieux, which respectively have a nuclear waste reprocessing plant and a nuclear power plant on their territory. The subtype of HM was dependent on age whereas clinical and biological data were the same, whatever the age. These results contribute to HM monitoring in an area where the nuclear industry is present and to improve the organization and follow-up of medical care.
    Revue d Épidémiologie et de Santé Publique 09/2012; 60(5):343-53. · 0.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: This study was designed to present the incidence of all the hematological malignancies in Basse-Normandie for 1997-2004. We extracted the data from the Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN), a French registry which belongs to the Association of the French Cancer Registries (FRANCIM). METHODS: All the malignant hematological diseases were coded using the third edition of the International Classification for Oncologic Diseases (ICDO-3) and the ADICAP classification, a special version adapted in 2001 for hematology. A total of 5510 new cases of malignant hematological disorders were registered over the 1997-2004 period. No significant difference in incidence was detected for any of the departments making up the Basse-Normandie region (Calvados, Manche and Orne). In men, the most frequent malignant disorders were non-Hodgkin malignant lymphomas (NHML) followed by chronic lymphocytic leukemia and other mature neoplasms, myelodysplastic syndromes (MDS), multiple myelomas (MM), myeloproliferative syndromes (MPS), acute myeloid leukemias (AML), Hodgkin lymphomas (HL), Waldenström macroglobulinemia (WM), and acute lymphoblastic leukemia (ALL). In women, MM is the third most frequent hematological disorder after NHML and lymphocytic leukemia followed by other mature neoplasms, MPS, MDS, AML, HL, WM, and ALL. The other hematological disorders are very rare. RESULTS: We provide the incidence for the main hematological disorders and for the first time present the incidence of the different subtypes of the HL and NHML, mature lymphoid neoplasms, MPD, and MDS. These results are useful for the organization and follow-up of medical care. The development of specialized hematology and active protocols can optimize the management of older patients. High-quality data remain necessary for continuous monitoring and research on patients with malignant hematological diseases.
    Revue d Épidémiologie et de Santé Publique 06/2009; · 0.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The study was designed to present the incidence of all the haematological malignancies in Basse-Normandie over the period 1997-2004. We extracted the data from the "Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN)", a French registry which belongs to the Association of the French Cancer Registries (FRANCIM). All the malignant haematological diseases were coded using the third edition of the International Classification for Oncologic Diseases (ICD-O-3) and the ADICAP classification, a special version adapted in 2001 for haematology. Five thousand five hundred and ten new cases of malignant haematological disorders were registered over the period 1997-2004. Whatever the department constituting the Basse-Normandie (Calvados, Manche and Orne), no significant difference of incidence was detected. In men, the more frequent malignant disorders were non-Hodgkin's malignant lymphomas (NHML) followed by chronic lymphocytic leukemia and other mature neoplasms, myelodysplastic syndromes (MDS), multiple myeloma (MM), myeloproliferative disorders (MPD), acute myeloid leukemias (AML), Hodgkin's lymphomas (HL), Waldenström's macroglobulinemia (WM) and acute lymphoblastic leukemia (ALL). In women, MM is the third more frequent haematological disorders after NHML and lymphocytic leukaemia and other mature neoplasms, MPD, MDS, AML, Hodgkin's lymphomas, WM and ALL. The other haematological disorders are very rare. We provide the incidence for the main haematological disorders and for the first time we also present the incidence of the different subtypes of the Hodgkin's and non-Hodgkin's malignant lymphomas, mature lymphoid neoplasms, MPD and also MDS. These results are useful for the organization and follow-up of medical care. The development of specialized haematology and active protocols can optimize the management of the older patients. A high quality of the collected data remains necessary for a continuous watching and research on patients with malignant haematological diseases.
    Revue d Épidémiologie et de Santé Publique 05/2009; 57(3):151-8. · 0.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The epidemiologic studies concerning the myelodysplastic syndromes (MDS) are limited and the crude incidence rate are heterogeneous, ranging from 1,0/100 000 in Japan and 9,3/100 000 in UK.We present the data from the Registre régional des hémopathies malignes de Basse-Normandie (National registry for malignant hemopathies in Basse-Normandie; RRHMBN). The myelodysplastic syndromes account for 13% of all the new cases of malignant hemopathies occurring in patients residing in Basse-Normandie, at diagnosis. Refractory anaemia are common and account for half of the MDS cases. The world-standardized incidence rates (WSR) are 2,55/100 000 +/- 0,22 overall, 3,64 +/- 0,38 in man and 1,78 +/- 0,25 in woman (sex ratio : 2,04). The WSR increases with age : 1,75/100 000 in 50-54 years and 24,03 et 37,83/100 000 in 70-74 and 75-79 years, respectively. The differences in incidence can be explained by the heterogeneity of MDS, exhaustivity of the data collection, diagnostic criteria and the use of different classification over time.The epidemiologic data emerging from a regional and specialized registry are important in developing epidemiologic strategy and improving the knowledge in MDS.
    Revue Francophone des Laboratoires 01/2009; 2009(413):25-29.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to provide updated estimates of national trends in cancer incidence and mortality for France for 1980-2005. Twenty-five cancer sites were analysed. Incidence data over the 1975-2003 period were collected from 17 registries working at the department level, covering 16% of the French population. Mortality data for 1975-2004 were provided by the Inserm. National incidence estimates were based on the use of mortality as a correlate of incidence, mortality being available at both department and national levels. Observed incidence and mortality data were modelled using an age-cohort approach, including an interaction term. Short-term predictions from that model gave estimates of new cancer cases and cancer deaths in 2005 for France. The number of new cancer cases in 2005 was approximately 320,000. This corresponds to an 89% increase since 1980. Demographic changes were responsible for almost half of that increase. The remainder was largely explained by increases in prostate cancer incidence in men and breast cancer incidence in women. The relative increase in the world age-standardised incidence rate was 39%. The number of deaths from cancer increased from 130,000 to 146,000. This 13% increase was much lower than anticipated on the basis of demographic changes (37%). The relative decrease in the age-standardised mortality rate was 22%. This decrease was steeper over the 2000-2005 period in both men and women. Alcohol-related cancer incidence and mortality continued to decrease in men. The increasing trend of lung cancer incidence and mortality among women continued; this cancer was the second cause of cancer death among women. Breast cancer incidence increased regularly, whereas mortality has decreased slowly since the end of the 1990s. This study confirmed the divergence of cancer incidence and mortality trends in France over the 1980-2005 period. This divergence can be explained by the combined effects of a decrease in the incidence of the most aggressive cancers and an increase in the incidence of less aggressive cancers, partly due to changes in medical practices leading to earlier diagnoses.
    Revue d Épidémiologie et de Santé Publique 07/2008; 56(3):159-75. · 0.69 Impact Factor
  • Xavier Troussard, Albert Collignon
    Soins. Chirurgie 04/2008;
  • Clinical Lymphoma Myeloma and Leukemia. 11:S200–S201.